Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond

Prasanna Santhanam; Lilja B. Solnes; Steven B. Rowe

doi:10.1007/s12032-017-1051-x

Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond

Prasanna Santhanam, Lilja B. Solnes, Steven B. Rowe

School of Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

An important aspect of differentiated thyroid cancer (DTC) management is disease localization by imaging. Functional imaging of thyroid cancer with iodinated radiotracers has been employed for metastatic disease detection for long. More recently, 2-deoxy-2-[18F] fluoro-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), a non-iodinated ubiquitous PET tracer, has been used to detect non-radioiodine (RAI) avid disease. Advances in molecular imaging have led to the development of newer tracers like 18F-TFB (18F-tetrafluoroborate) that are transported through the sodium–iodide symporter (NIS) as well as 68 Ga-DOTATATE that image the somatostatin receptors sub-type 2 expressed in medullary thyroid cancer and some DTC. In coming years, there will be focus on newer receptor targets like prostate-specific membrane antigen expression and endoradiotherapies and theranostics.

Original language	English (US)
Article number	189
Journal	Medical Oncology
Volume	34
Issue number	12
DOIs	https://doi.org/10.1007/s12032-017-1051-x
State	Published - Dec 1 2017

Keywords

Differentiated Thyroid Cancer
Imaging
Radiotracers

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1007/s12032-017-1051-x

Cite this

@article{dbd964638fd3429e91a728111c214e69,

title = "Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond",

abstract = "An important aspect of differentiated thyroid cancer (DTC) management is disease localization by imaging. Functional imaging of thyroid cancer with iodinated radiotracers has been employed for metastatic disease detection for long. More recently, 2-deoxy-2-[18F] fluoro-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), a non-iodinated ubiquitous PET tracer, has been used to detect non-radioiodine (RAI) avid disease. Advances in molecular imaging have led to the development of newer tracers like 18F-TFB (18F-tetrafluoroborate) that are transported through the sodium–iodide symporter (NIS) as well as 68 Ga-DOTATATE that image the somatostatin receptors sub-type 2 expressed in medullary thyroid cancer and some DTC. In coming years, there will be focus on newer receptor targets like prostate-specific membrane antigen expression and endoradiotherapies and theranostics.",

keywords = "Differentiated Thyroid Cancer, Imaging, Radiotracers",

author = "Prasanna Santhanam and Solnes, {Lilja B.} and Rowe, {Steven B.}",

year = "2017",

month = dec,

day = "1",

doi = "10.1007/s12032-017-1051-x",

language = "English (US)",

volume = "34",

journal = "Medical Oncology",

issn = "1357-0560",

publisher = "Humana Press",

number = "12",

}

TY - JOUR

T1 - Molecular imaging of advanced thyroid cancer

T2 - iodinated radiotracers and beyond

AU - Santhanam, Prasanna

AU - Solnes, Lilja B.

AU - Rowe, Steven B.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - An important aspect of differentiated thyroid cancer (DTC) management is disease localization by imaging. Functional imaging of thyroid cancer with iodinated radiotracers has been employed for metastatic disease detection for long. More recently, 2-deoxy-2-[18F] fluoro-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), a non-iodinated ubiquitous PET tracer, has been used to detect non-radioiodine (RAI) avid disease. Advances in molecular imaging have led to the development of newer tracers like 18F-TFB (18F-tetrafluoroborate) that are transported through the sodium–iodide symporter (NIS) as well as 68 Ga-DOTATATE that image the somatostatin receptors sub-type 2 expressed in medullary thyroid cancer and some DTC. In coming years, there will be focus on newer receptor targets like prostate-specific membrane antigen expression and endoradiotherapies and theranostics.

AB - An important aspect of differentiated thyroid cancer (DTC) management is disease localization by imaging. Functional imaging of thyroid cancer with iodinated radiotracers has been employed for metastatic disease detection for long. More recently, 2-deoxy-2-[18F] fluoro-d-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT), a non-iodinated ubiquitous PET tracer, has been used to detect non-radioiodine (RAI) avid disease. Advances in molecular imaging have led to the development of newer tracers like 18F-TFB (18F-tetrafluoroborate) that are transported through the sodium–iodide symporter (NIS) as well as 68 Ga-DOTATATE that image the somatostatin receptors sub-type 2 expressed in medullary thyroid cancer and some DTC. In coming years, there will be focus on newer receptor targets like prostate-specific membrane antigen expression and endoradiotherapies and theranostics.

KW - Differentiated Thyroid Cancer

KW - Imaging

KW - Radiotracers

UR - http://www.scopus.com/inward/record.url?scp=85032579090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032579090&partnerID=8YFLogxK

U2 - 10.1007/s12032-017-1051-x

DO - 10.1007/s12032-017-1051-x

M3 - Review article

C2 - 29086115

AN - SCOPUS:85032579090

SN - 1357-0560

VL - 34

JO - Medical Oncology

JF - Medical Oncology

IS - 12

M1 - 189

ER -

Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this